DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

China In-Depth

Assess commercial opportunities and optimize your strategies in China with comprehensive China pharma market data and insights for ten key indications that include:

  • Non-small cell lung cancer
  • Hepatocellular carcinoma
  • Rheumatoid arthritis
  • Non-alcoholic fatty liver disease (NASH)
  • Multiple sclerosis
  • Gastric cancer
  • Colorectal cancer
  • Type 2 diabetes
  • Squamous cell carcinoma of the head and neck
  • Bladder cancer

We have prioritized these indications based on China’s epidemiology landscape, clinical unmet needs, and commercial opportunities. Our solution features broad, deep, and geographically diverse primary market research with five thought-leading physician interviews and 50 physician surveys per indication.

Schedule a demo

Key Features

  • World-class China epidemiology, segmented by rural and urban populations
  • Keen insight into the complex access and reimbursement environment
  • Detailed analysis of current treatment paradigms including interviews with Chinese physicians
  • In-depth early stage and late stage China drug pipeline coverage
  • 10-year, annualized, China drug-level sales forecasts supported by detailed primary and secondary research
China represents a $140 billion pharmaceutical market- the second largest in the world- with rapid growth projected in the years to come. Although national insurance coverage has broadened and regulatory pathways have become more streamlined, enormous differences remain between China’s urban and rural markets, along with a lack of overall market transparency. Our China In-Depth solution allows you to:
  • Accurately quantify market potential for your pipeline assets;
  • Understand the commercial impact of new brands, generics, and key China pharma market events; and
  • Optimize your clinical development and long-term strategies.